Bristol Myers Squibb (BMS) has announced an agreement with Nvidia, a technology company providing graphics processing units (GPUs) and software infrastructure required to power artificial intelligence (AI), high-performance computing, and advanced 3D graphics, to expand its computing infrastructure for AI. 

The investment will add an Nvidia DGX SuperPOD with DGX Vera Rubin NVL72 systems to provide BMS’scientific and computational teams access to a change in both computational power and efficiency to enable BMS to pursue larger AI workloads without a proportional increase in energy consumption. 

The investment builds on nearly three years of collaboration that began when BMS first deployed NVIDIA DGX SuperPOD infrastructure to support its research and development activities and marks the next step in expanding that foundation to match the growing scope of BMS’s AI-driven scientific programs across oncology, hematology, cardiovascular, immunology and neuroscience. 

The expanded agreement advances BMS’ vision of hybrid intelligence, a model of scientific work where AI co-scientists and human researchers operate in close coordination, with AI systems handling the execution of complex, data-intensive tasks while scientists focus on direction, interpretation, and the decisions that require human expertise. The Vera Rubin cluster will serve as the computational backbone for this vision to supporting the development of foundation models trained on BMS’ proprietary data and, where the science calls for it, drawing on domain-specific capabilities from BioNeMo, Nvidia’s platform for biological AI while powering the agentic workflows that allow researchers to evaluate hypotheses at a scale. 

Source: Bristol Myers Squibb